Abacus Medicine Group acquires Delfarma
15.09.2026
We advised Abacus Medicine Group, one of Europe’s leading pharmaceutical companies specialising in the parallel distribution of medicines, on its acquisition of Delfarma, one of Poland’s leading parallel importers of medicines.
We provided comprehensive legal support at every stage of the transaction, including the structuring of the transaction, legal due diligence, the preparation and negotiation of the transaction documentation, and advice on the merger control process.
The parties signed the preliminary share purchase agreement on 14 September 2026. Completion of the acquisition remains subject to clearance by the Polish Competition Authority.
Our legal team was led by Jakub Lerner (partner, M&A), with Kacper Czubacki (counsel, M&A) coordinating the transactional workstream. The core transaction team also included Piotr Ząbkiewicz (M&A), Adrian Budny (M&A), Karolina Romanowska (M&A), Joanna Krakowiak (partner, regulatory), Karolina Hryckowian (regulatory), and Julia Padlewska-Oleksy (IP/IT).
The due diligence work was additionally supported by Karolina Romanowska (GDPR), Lena Marcinoska-Boulangé (IP/IT), Marcin Rżysko (real estate), Natalia Bigowska (employment), and Adrianna Ogonowska (environment).
Abacus Medicine Group is a Danish-headquartered international pharmaceutical group and one of the leading players in the European parallel distribution market. Founded in 2004, the Group supplies prescription medicines to customers in more than 40 countries and operates across pharmaceutical trading, pharmaceutical production and pharmaceutical wholesaling. With approximately EUR 1.8 billion in revenue and 1,750 employees in 2025, Abacus Medicine Group is a significant player in the European pharmaceutical market.